1KARATZA A A, BUSH A, MAGEEA G, Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension[J]. Int J Cardiol,2005,100:267-273. 被引量：1
2CHOCKALINGAM A, VENKATESAN G, VEN KATESAN S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension [J].Int J Cardiol,2005,99 : 91-95. 被引量：1
6HUMBERT M, KHALTAEV N, BOUSQUET J, et al. Pulmonary hypertension: from an orphan disease to a public health problem[J]. Chest, 2007,132:365 -367. 被引量：1
7GALIE N, HOEPER M M, HUMBERT M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2009,30: 2493 - 2537. 被引量：1
8SATOH T, SAJI T, WATANABE H, et al. A Phase III, multicenter, collaborative, open-Label clin- ical trial of cildenafil in Japanese patients with pulmonary arterial hypertension[J].Cir J,2011,75:677-- 682. 被引量：1
9GALIE N, BRUNDAGE B H, GHOFRANI H A, et al. Tadalafil therapy for pulmonary arterial hypertension[J]. Circulation, 2009,119 : 2894- 2903. 被引量：1
10LEE D S, KIM Y K, JUNG Y W. Simvastatin, sildenafil and their Combination in monocrotaline induced pulmonary aterial hypertension[J]. Korean Cire J,2010,40:659-664. 被引量：1
